Intellectual Property
To support its claims and provide marketing protection, Akesis has developed a broad intellectual property portfolio that includes several issued patents (see table below). This patent portfolio is being prosecuted domestically and internationally, and encompasses compositions and uses of matter, delivery in multiple consumer-oriented forms, delivery alone and in combination with other agents (including all classes of diabetes therapeutic agents), and methods for treatment and diagnoses. Following are highlights of key patent claims:
- A method for treating daily blood glucose fluctuations
- A method for treating elevated A1C levels
- A method for improving the ability of a subject to metabolize glucose
- A method for reducing the dosage of anti-diabetic medication needed for diabetes treatment, where said anti-diabetic medication comprises one or more of insulin, a thiazolidinedione, a sulfonylurea, an α-glucosidase inhibitor or a benzoic acid derivative
- A composition for the treatment of diabetes comprising metformin, (magnesium), (chromium), and (vanadium), which components synergistically treat diabetes
- Improve glucose metabolism in a pre-diabetic subject
- (Treatment of) a condition selected from the group consisting of atherosclerosis, heart disease, hyperglyceride, and hypertriglyceride
Akesis Portfolio of Issued Patents
US Patent Number Title Date of Patent For Detailed Information:
- 5,962,030 - Dietary Supplement and Method of Treatment for Diabetic Control, October 5, 1999
- 6,203,819 - Dietary Supplement and Method of Treatment for Diabetic Control, March 20, 2001
- 6,376,549 - Metformin-Containing Compositions for the Treatment of Diabetes, April 23, 2002
- 6,852,760 - Compositions and Methods for Treatment for Glucose Metabolism Disorders, February 8, 2005
Initial studies suggest that several of Akesis’ patented formulations have the potential to be superior to drugs currently on the market.